New combo therapy shows promise in slowing spread of prostate cancer
NCT ID NCT04037358
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 19 times
Summary
This study tested whether adding a bone-targeting drug (Radium-223) to precise radiation therapy (SABR) helps men with prostate cancer that has spread to a few spots (oligometastatic). Sixty-four men participated, and the main goal was to see how long the cancer stayed under control. The approach aims to delay disease progression, not cure the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.